 | Vol. 15.26 – 5 November, 2024 |
| |
|
|
| Investigators reported for the first time autologous transplantation of chemically induced pluripotent stem cell-derived islets into a patient with type 1 diabetes with immunosuppression as part of an exploratory clinical study. [Cell] |
|
|
|
 | PUBLICATIONSListed by the impact factor of the journal |
| |
|
|
| The authors profiled single-nuclei RNA along with enhancer marks H3K4me1 or H3K27ac in islets from lean or obese mice. They identified distinct gene signatures and enhancer states correlating with β cell dysfunction trajectory. [Nature Communications] |
|
|
|
| Investigators described in vitro characterization of the secretory function of pancreatic islets, derived from transgenic pigs expressing the glucagon-like-peptide-1-1M3R cassette under the porcine insulin promoter, and their usage to treat insulin-dependent diabetes in an immunodeficient mouse model. [Proceedings of The National Academy of Sciences of The United States of America] |
|
|
|
| The aim of this Phase II, placebo-controlled, double-blinded, randomized clinical trial was to investigate the efficacy and safety of fenofibrate in adults and adolescents with newly diagnosed type 1 diabetes. [Diabetologia] |
| |
|
|
| Investigators reported a previously unknown chemo-induced symbiotic signaling circuit that adaptively conferred chemoresistance in patients and mice with advanced PDAC. [Cell Discovery] |
|
|
|
| Researchers tested prophylactic and therapeutic vaccination against ADAM12 in murine pancreatic ductal adenocarcinoma and observed delayed tumor growth along with a reduction in cancer-associated fibroblasts and tumor desmoplasia. [EMBO Molecular Medicine] |
|
|
|
| Baseline plasma levels of chemokine chemokine ligand 3 (CCL3) were integrated with clinical outcomes in PDAC patients treated with galunisertib plus gemcitabine or placebo plus gemcitabine. [NPJ Precision Oncology] |
|
|
|
| Scientists demonstrated that KRASG12D induced the expression of an endogenous inhibitor of protein phosphatase 2A (PP2A) activity, cancerous inhibitor of PP2A (CIP2A), and phosphorylation of the PP2A substrate, c-MYC. [Oncogene] |
|
|
|
| Investigators unveiled a multistep process for interleukin 17 receptor B (IL-17RB) upregulation at the invasive margin, which occured through direct communication between tumor cells and fibroblasts. [Cancer Gene Therapy] |
|
|
|
| Researchers created a recombinant Newcastle disease virus containing the PTEN gene to investigate its PDAC cell-killing and tumor-suppression effects in PDAC cells transplanted into mice. [Molecular Therapy Oncology] |
|
|
|
| Scientists investigated the utility of patient-derived organoids (PDOs) to overcome the obstacles of detecting somatic mutations and enhance somatic mutation identification. Surgically resected PDAC tumors and their paired PDOs from 21 patients were examined. [Scientific Reports] |
|
|
|
|
| The authors summarize the evidence regarding the epidemiology of type 1 diabetes mellitus in older adults as well as the genetics, immunology, and diagnostic challenges. [Nature Reviews Endocrinology] |
|
|
|
|
| With a $50 million gift from Richard and Susan Rogel, the University of Michigan Health Rogel Cancer Center aims to revolutionize how the world detects, treats, and ultimately cures pancreatic cancer. [Michigan Medicine] |
|
|
|
| The University of Oxford has been given a share of £2 million to study whether saliva from parasitic ticks could remove the need for immunosuppressant drugs when treating type 1 diabetes. [BBC] |
|
|
|
|
| December 2-3, 2024 Toronto, Ontario, Canada & Online |
|
|
|
|
|
| University of New Mexico – Albuquerque, New Mexico, United States |
|
|
|
| City of Hope – Monrovia, California, United States |
|
|
|
| University of Pennsylvania – Philadelphia, Pennsylvania, United States |
|
|
|
| University of Oklahoma Health Sciences Center – Oklahoma City, Oklahoma, United States |
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
|